TY  - BOOK
AU  - Debnath, Dipanjan 
TI  - The Role of Immunotherapy in Pancreatic Cancer. [Review]
SN  - 1198-0052
PY  - 2022///
KW  - *Adenocarcinoma
KW  - *Pancreatic Neoplasms
KW  - Humans
KW  - Immunologic Factors
KW  - Immunotherapy
KW  - Pancreatic Neoplasms/dt [Drug Therapy]
KW  - Pancreatic Neoplasms/pa [Pathology]
KW  - MedStar Washington Hospital Center
KW  - Internal Medicine Residency
KW  - Journal Article
KW  - Review
N1  - Available online through MWHC library: 2006 - present
N2  - Pancreatic adenocarcinoma remains one of the most lethal cancers globally, with a significant need for improved therapeutic options. While the recent breakthroughs of immunotherapy through checkpoint inhibitors have dramatically changed treatment paradigms in other malignancies based on considerable survival benefits, this is not so for pancreatic cancer. Chemotherapies with modest benefits are still the cornerstone of advanced pancreatic cancer treatment. Pancreatic cancers are inherently immune-cold tumors and have been largely refractory to immunotherapies in clinical trials. Understanding and overcoming the current failures of immunotherapy through elucidating resistance mechanisms and developing novel therapeutic approaches are essential to harnessing the potential durable benefits of immune-modulating therapy in pancreatic cancer patients
UR  - https://dx.doi.org/10.3390/curroncol29100541
ER  -